|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.300 SEK | +1.53% |
|
+2.91% | +15.22% |
| 07-25 | Active Biotech Doses First Patient in Amended Ho172 Clinical Study of Tasquinimod in Myelofibrosis | CI |
| 07-24 | Active Biotech Doses First Patient in Amended Tasquinimod Myelofibrosis Trial | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Neutral |
| Resistance | 5.5 | 8.08 | 14.52 |
| Spread/Res. | -3.64% | -34.41% | -63.50% |
| Spread/Supp. | +3.92% | +39.47% | +38.02% |
| Support | 5.1 | 3.8 | 3.84 |
- Stock Market
- Stocks
- ACTI Stock
- ACTI Stock
- Charts Active Biotech AB
Select your edition
All financial news and data tailored to specific country editions
